NO20072704L - Oral solid dosage forms containing a low oestradiol dose - Google Patents

Oral solid dosage forms containing a low oestradiol dose

Info

Publication number
NO20072704L
NO20072704L NO20072704A NO20072704A NO20072704L NO 20072704 L NO20072704 L NO 20072704L NO 20072704 A NO20072704 A NO 20072704A NO 20072704 A NO20072704 A NO 20072704A NO 20072704 L NO20072704 L NO 20072704L
Authority
NO
Norway
Prior art keywords
dosage forms
dose
low
oral solid
solid dosage
Prior art date
Application number
NO20072704A
Other languages
Norwegian (no)
Inventor
Torsten Wagner
Adrian Funke
Kristina Mueller
Christian Zurth
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20072704L publication Critical patent/NO20072704L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Den foreliggende oppfinnelse angår orale faste doseformer som inneholder en svært lav østradioldose. Doseformene er formulert med henblikk på å unngå degradering av østradiolet og å minimere polyvinylpyrrolidoninnholdet, mens tilsvarende hurtig oppløsning av østradiolet fortsatt oppnås. Doseformene er nyttige i forebygging eller behandling av en fysisk tilstand hos en kvinne forårsaket av utilstrekkelige endogene østradiolnivaerThe present invention relates to oral solid dosage forms containing a very low estradiol dose. The dosage forms are formulated to avoid degradation of the estradiol and to minimize the polyvinylpyrrolidone content, while correspondingly rapid dissolution of the estradiol is still achieved. The dosage forms are useful in preventing or treating a physical condition in a woman caused by insufficient endogenous estradiol levels.

NO20072704A 2004-11-02 2007-05-29 Oral solid dosage forms containing a low oestradiol dose NO20072704L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04078014 2004-11-02
PCT/EP2005/011726 WO2006048261A2 (en) 2004-11-02 2005-11-01 Oral solid dosage forms containing a low dose of estradiol

Publications (1)

Publication Number Publication Date
NO20072704L true NO20072704L (en) 2007-05-29

Family

ID=34928627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072704A NO20072704L (en) 2004-11-02 2007-05-29 Oral solid dosage forms containing a low oestradiol dose

Country Status (21)

Country Link
EP (1) EP1814526A2 (en)
JP (1) JP2008518895A (en)
KR (1) KR20070085558A (en)
CN (1) CN101094656A (en)
AR (1) AR053650A1 (en)
AU (1) AU2005300658A1 (en)
BR (1) BRPI0517940A (en)
CA (1) CA2585095A1 (en)
CR (1) CR9112A (en)
CU (1) CU20070094A7 (en)
EA (1) EA013262B1 (en)
GT (1) GT200500315A (en)
IL (1) IL182635A0 (en)
MX (1) MX2007005281A (en)
NO (1) NO20072704L (en)
PA (1) PA8651401A1 (en)
PE (1) PE20061126A1 (en)
TW (1) TW200621312A (en)
UY (1) UY29185A1 (en)
WO (1) WO2006048261A2 (en)
ZA (1) ZA200705012B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
KR20080047957A (en) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 Pharmaceutical composition for the treatment and prevention of hypertension
DE102009007771B4 (en) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Buccal administration system containing 17α-estradiol
JP5852639B2 (en) 2010-04-15 2016-02-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Low dose solid oral dosage form for HRT
KR20130097073A (en) 2010-04-15 2013-09-02 바이엘 인텔렉쳐 프로퍼티 게엠베하 Very low-dosed solid oral dosage forms for hrt
CN112516149B (en) * 2020-07-21 2023-07-18 南方医科大学 Application of estradiol benzoate or its pharmaceutically acceptable salt in the preparation of anti-coronavirus medicine
JP2024000555A (en) * 2022-06-21 2024-01-09 東ソー株式会社 Method for producing estradiol measurement reagent under ultraviolet ray suppression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125071C (en) * 1963-12-24
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
FR2739558B1 (en) * 1995-10-05 1997-11-28 Innothera Lab Sa UNITAL GALENIC FORM FOR LOCAL HORMONOTHERAPY OF VAGINAL DROUGHT
FR2754179B1 (en) * 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
EP3747443A3 (en) * 2000-12-15 2021-03-03 Novo Nordisk Health Care AG Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis
FR2823976A1 (en) * 2001-04-25 2002-10-31 Theramex NOVEL HORMONAL COMPOSITION AND ITS USE
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JP2004155779A (en) * 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd Oral composition for prevention and treatment of menopause

Also Published As

Publication number Publication date
KR20070085558A (en) 2007-08-27
BRPI0517940A (en) 2008-10-21
TW200621312A (en) 2006-07-01
ZA200705012B (en) 2008-10-29
EP1814526A2 (en) 2007-08-08
WO2006048261A3 (en) 2006-09-21
WO2006048261A2 (en) 2006-05-11
GT200500315A (en) 2006-06-06
AR053650A1 (en) 2007-05-16
PA8651401A1 (en) 2006-12-07
CR9112A (en) 2007-11-23
AU2005300658A1 (en) 2006-05-11
EA200700979A1 (en) 2007-10-26
CA2585095A1 (en) 2006-05-11
JP2008518895A (en) 2008-06-05
CN101094656A (en) 2007-12-26
EA013262B1 (en) 2010-04-30
CU20070094A7 (en) 2009-09-08
MX2007005281A (en) 2008-03-11
UY29185A1 (en) 2006-05-31
IL182635A0 (en) 2007-07-24
PE20061126A1 (en) 2006-11-11

Similar Documents

Publication Publication Date Title
EA200900491A1 (en) USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN
MXPA04004842A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
MXPA04004837A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO20072518L (en) The gender stereoid proceeds alone or in combination with a selective estrogen receptor modulator and / or with oestrogens and / or a type 5 CGMP phosphodiesterase inhibitor to prevent or treat vaginal dryness and sexual dysfunction in postmenopausal women.
RU2009148278A (en) The use of estriol in a low dose
SE0001899D0 (en) New compounds
CY1111698T1 (en) COMBINATION INCLUDING AN AT1 COMPETITIVE RECEPTOR AND AN INSULIN EXTRACTOR OR A INSULIN SENSITIVE
TW200517107A (en) Novel formulation
EE05259B1 (en) Use of antiprogestins for the prophylaxis and treatment of hormone dependent diseases
PL402550A1 (en) Intravaginal pharmaceutical composition and the use of a peroxide source and a bioadhesive carrier
DE50109650D1 (en) TOPICAL TREATMENT IN MASTALGIA
CU20070094A7 (en) SOLID ORAL DOSAGE FORMS CONTAINING A LOW ESTRADIOL DOSE
EA200500671A1 (en) PHARMACEUTICAL COMPOSITION OF OLANZAPIN
HUP0101005A2 (en) Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
NO20065471L (en) Use of IL-6 for the treatment or prevention of chemotherapy-induced neuropathy.
EA200701389A1 (en) SOLID ORAL MEDICAL FORM FOR CONTRACEPTION
MX2007009061A (en) Contraceptive pharmaceutical preparation.
CY1112775T1 (en) USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA
BR0215352A (en) Pharmaceutical composition comprising an alpha-glycosidase inhibitor and a 4-oxobutanoic acid, and their use to treat diabetes
SE9902673D0 (en) New composition
UA90076C2 (en) Low concentration peroxide for treating or preventing vaginal infections
DK1910398T3 (en) 17-alpha-substituted derivatives of estradiol with wound healing effect
BR0301633A (en) Pharmaceutical composition employing stevioside

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application